Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory

Havekes, Robbert; Park, Alan J.; Tolentino, Rosa E.; Bruinenberg, Vibeke M.; Tudor, Jennifer C.; Lee, Yool; Hansen, Rolf T.; Guercio, Leonardo A.; Linton, Edward; Neves-Zaph, Susana R.

Published in:
The Journal of Neuroscience

DOI:
10.1523/JNEUROSCI.0248-16.2016

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Behavioral/Cognitive

Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory

Robbert Havekes,1,2 Alan J. Park,2 Rosa E. Tolentino,3 Vibek M. Bruinenberg,1 Jennifer C. Tudor,2 Yool Lee,3 Rolf T. Hansen,2 Leonardo A. Guercio,2 Edward Linton,2 Susana R. Neves-Zaph,4 Peter Meerlo,1 George S. Baillie,5 Miles D. Houslay,6 and Ted Abel2

1Groningen Institute for Evolutionary Life Sciences, University of Groningen, 9700 AB, Groningen, The Netherlands, 2Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, 3Department of Systems Pharmacology and Translational Therapeutics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, 4Departments of Pharmacology and Systems Therapeutics, Friedman Brain Institute, and System Biology Center New York, Icahn School of Medicine at Mount Sinai, New York, New York 10029, 5Institute of Cardiovascular and Medical Science, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom, and 6Institute of Pharmaceutical Science, King’s College London, London SE1 9NH, United Kingdom

Alterations in cAMP signaling are thought to contribute to neurocognitive and neuropsychiatric disorders. Members of the cAMP-specific phosphodiesterase 4 (PDE4) family, which contains >25 different isoforms, play a key role in determining spatial cAMP degradation so as to orchestrate compartmentalized cAMP signaling in cells. Each isoform binds to a different set of protein complexes through its unique N-terminal domain, thereby leading to targeted degradation of cAMP in specific intracellular compartments. However, the functional role of specific compartmentalized PDE4 isoforms has not been examined in vivo. Here, we show that increasing protein levels of the PDE4A5 isoform in mouse hippocampal excitatory neurons impairs a long-lasting form of hippocampal synaptic plasticity and attenuates hippocampus-dependent long-term memories without affecting anxiety. In contrast, viral expression of a truncated version of PDE4A5, which lacks the unique N-terminal targeting domain, does not affect long-term memory. Further, overexpression of the PDE4A1 isoform, which targets a different subset of signalosomes, leaves memory undisturbed. Fluorescence resonance energy transfer sensor-based cAMP measurements reveal that the full-length PDE4A5, in contrast to the truncated form, hampers forskolin-mediated increases in neuronal cAMP levels. Our study indicates that the unique N-terminal localization domain of PDE4A5 is essential for the targeting of specific cAMP-dependent signaling underlying synaptic plasticity and memory. The development of compounds to disrupt the compartmentalization of individual PDE4 isoforms by targeting their unique N-terminal domains may provide a fruitful approach to prevent cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with alterations in cAMP signaling.

Key words: cAMP; hippocampus; LTP; memory; PDE; phosphodiesterase

Introduction

The cAMP signaling pathway plays an essential role in synaptic plasticity and memory (Havekes and Abel, 2009). Local degradation of cAMP within specific intracellular compartments is precisely orchestrated by cAMP-degrading phosphodiesterases (PDEs; Houslay, 2010; Mika et al., 2012). Isoforms of the PDE4 subfamily have a prominent role in regulating cAMP signaling in the mammalian brain (Houslay and Adams, 2003; O’Donnell and Zhang, 2004; Sanderson and Sher, 2013), in Drosophila (Conti and Jin, 1999), and in the Aplysia nervous system (Park et al., 2005). Although the catalytic cAMP-degrading domain of the PDE4 isoforms is highly conserved, all of the >25 described iso-
forms have a unique N-terminal domain that targets each isoform to specific intracellular compartments, where it binds to a unique set of protein complexes (Houslay, 2010). Pharmacological suppression of PDE4 activity promotes synaptic plasticity and memory (Randt et al., 1982; Barad et al., 1998; Rutten et al., 2009; Werenicz et al., 2012). The PDE4 selective inhibitor, rolipram, prevents memory deficits associated with sleep loss (Vecsey et al., 2009), traumatic brain injury (Titus et al., 2013), aging (Wimmer et al., 2012), muscarinic or NMDA receptor blockade (Egawa et al., 1997; Zhang and O’Donnell, 2000; Wiescholleck and Manahan-Vaughan, 2012), and mouse models of Alzheimer’s disease (Gong et al., 2004; Renerken et al., 2009; Richter et al., 2013). However, the clinical use of broad PDE4 inhibitors is limited due to undesirable side effects, including emesis and diarrhea (Zeller et al., 1984; Bertolino et al., 1988; Spina, 2008). To circumvent these issues, which compromise the clinical use of pan-PDE4 inhibitors, studies are needed to identify which PDE4 isoforms target signaling complexes critical for cognitive processes and then to exploit such data to develop isoform-specific inhibitor approaches.

The PDE4 family is encoded by four genes (PDE4A–PDE4D; Houslay, 2010). PDE4B knock-out mice perform normally in hippocampus–dependent learning paradigms (Stciacca et al., 2008), but display an anxiogenic-like phenotype (Zhang et al., 2008), a phenotype also observed in mice lacking PDE4A isoforms (Hansen et al., 2014). Importantly, recent work revealed that the PDE4A family is not involved in emesis (Hansen et al., 2014), in contrast to the PDE4D subfamily (Robichaud et al., 2002). Mice lacking all PDE4D isoforms display either memory enhancements or impairments, depending on the task used (Rutten et al., 2008; Li et al., 2011). Although these mutant mouse models provide insight into the role of PDE4 family in plasticity and memory, they lack the resolution needed to identify which individual isoforms orchestrate the observed behavioral and cognitive phenotypes.

The importance of studying individual PDE family members is underscored by the complex regulation of isoform expression, which includes multiple promoters, alternative mRNA splicing, and alternative translational initiation sequences (Houslay et al., 2007). Expression levels of individual PDE4 isoforms are altered in traumatic brain injury (Olive et al., 2012), autism spectrum disorders, schizophrenia, and bipolar disorder (Braun et al., 2007; Fatemi et al., 2008a,b) by electroconvulsive shock delivery and treatment with antidepressants (Takahashi et al., 1999; D’Sa et al., 2005). Changes in cerebellar expression levels of PDE4A4, the human ortholog of rodent PDE4A5, are observed in patients with autism or bipolar disorder (Braun et al., 2007; Fatemi et al., 2008a). Further, PDE4A4/5 levels are upregulated in the lung tissue of patients with chronic obstructive pulmonary disease (COPD; Barber et al., 2004). Interestingly, COPD patients frequently experience sleep loss (Crinon and McNicholas, 2014), a condition that elevates PDE4A5 protein expression in the mouse hippocampus without affecting levels of other PDE4 isoforms (Vecsey et al., 2009). Although these findings suggest that memory impairments may be associated with altered PDE4A4/5 expression, it is unclear whether PDE4A4/5 in healthy conditions targets signaling mechanisms that are critical for memory. In the present study, we used a viral approach to increase the mouse PDE4A5 protein levels selectively in hippocampal excitatory neurons in vivo to assess the impact of elevated PDE4A5 expression on hippocampal synaptic plasticity and memory.

**Materials and Methods**

**Subjects.** C57BL/6J male mice (2–3 months of age) were obtained from The Jackson Laboratory at 6 weeks of age and housed in groups of four with littermates on a 12 h light/dark schedule with lights on at 7:00 A.M. [zeitgeber time (ZT0)]. Mice had food and water available ad libitum. Mice underwent surgery at 8–12 weeks of age, were individually housed for 5 d to recover from surgery, and then were pair housed throughout the experiment. For all behavioral experiments, mice were handled in the experimental room for 5 d for 1 min/d. All experiments were conducted according to National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.

**Virion injections.** The adeno-associated viruses (AAVs) were injected using a nanoFL 33 ga beveled needles (WPI) attached to a 10 μl Hamilton syringe controlled by a microsyringe pump (model UMP3, WPI) at the following sites (anteroposterior, −1.9 mm from bregma; dorsoventral, ±1.5 mm from bregma; and 1.5 mm below bregma), as described previously (Havekes et al., 2014). The needle was slowly lowered to the target site over the course of 3 min and remained at the target site for 1 min before the beginning of the injection (0.2 μl/min). Approximately 1 μl (corrected for genome copy number between constructs) was injected per hippocampus. After the injection, the needle remained at the target site for 1 min and then was slowly removed over a 5 min period.

**DNA manipulation and virus constructs.** Full-length rat PDE4A5 and mouse PDE4A1 constructs were based on GenBank accession numbers L27057.1 and M26715. The truncated PDE4A5 that lacks the first 303 bp encoding the isoform–unique N-terminal domain (referred to as PDE4A3; Bolger et al., 2003) was generated using standard PCR cloning procedures and the Stratagene FluUltra High-Fidelity DNA polymerase. pAAVp-CaMKIIa0.4-PDE4A5-VSV, pAAVp-CaMKIlo.4-PDE4A4-A4HA, pAAVp-CaMKIlo.4-HA, pAAVp-CaMKIlo.4-eGFP were produced through standard methods and packaged by the Penn Vector Core at the University of Pennsylvania. Titers ranged from 1.06 × 1010 to 2.02 × 1013 genome copy numbers. A 0.4 kb CaMKII promoter fragment (Dittgen et al., 2004) was used to drive expression selectively in excitatory neurons.

**Biochemistry.** ELISA-based assay kits (ENZO Life Sciences) were used to measure cAMP content following the manufacturer instructions. PDE activity assays and Western blots were conducted as described previously (Vecsey et al., 2009). For all other protein analyses, tissue lysates were prepared in Tris 50 mM, pH 9, sodium deoxycholate 1%, sodium fluoride 50 mM, activated sodium vanadate 20 μM, EDTA 20 μM, and β-glycerophosphate 40 μM. Protease inhibitors (Roche) and phosphatase inhibitors (Thermo Scientific) were added to the freshly prepared buffer just before tissue lysates. Samples were centrifuged for 10 min at

**References.**


This research was supported by Netherlands Organization for Scientific Research NWO-Rubicon Grant 820.07.029 (to R.H.), the University of Pennsylvania Research Foundation (to R.H. and T.A.); National Institutes of Health Grants 1R01-MH-086415 (to T.A.); AG-017626 (to T.A.), P50-CA-133300 (to J.C.T., Y. Paterson Principal Investigator), and S501-DK-087650 (to S.R.N.-Z.); and Systems Biology Center of New York Grant P50GM071558 (to S.R.N.-Z.). G.S.B. is supported by Medical Research Council Grant MR/J007412/1. R.H. is supported by the Einsteinium Foundation. T.A. is the Brush Family Professor of Biology at the University of Pennsylvania. We thank other Abel laboratory members for their help with these experiments and for their comments on this manuscript. We also thank Jin Zhang for providing pC6E3.

The authors declare no competing financial interests.

This article is freely available online through the J Neurosci Author Open Choice option.
13,000 × g at 4°C, and supernatant was collected. Protein concentration of the samples was measured using the Bradford method. LDS sample buffer (Nupage, Invitrogen) including β-mercaptoethanol was added, and samples were boiled for 5 min before loading on Criterion TGX 18-well 4–20% gels (Bio-Rad). After electrophoresis, proteins were transferred to PVDF membrane followed by blocking for 1 h in 5% milk in TBST. After blocking, membranes were incubated in 5% milk or BSA with one of the following antibodies: GAPDH (1:1000; K1511, Santa Cruz Biotechnology); PDE4A4 (1:1000; Vecsey et al., 2009); PDE4A5 (1:1000; Vecsey et al., 2009); HA tag (1:1000; catalog #1867423, Roche); and vescalir stomatitis virus (VSV) tag (1:3000; catalog #1874, Abcam). After incubation with the primary antibodies, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature (1:1000, mouse secondary antibody, sc-2318, Santa Cruz Biotechnology; 1:5000, rabbit secondary antibody, sc-2030, Santa Cruz Biotechnology; rat secondary antibody, sc-2032, 1:1000, Santa Cruz Biotechnology). The immunoreactive bands were captured on autoradiography film (Kodak) and analyzed using ImageJ (NIH).

Immunohistochemistry. Immunohistochemistry was conducted as described previously (Isiegas et al., 2008). The following antibodies or combinations of antibodies were used: PDE4A5 (1:200; Vecsey et al., 2009); HA tag (1:200; catalog #1867423, Roche); VSV tag (1:2000; catalog #1874, Abcam); GFP-Alexa Fluor 594 (1:300; catalog #43202, Millipore); followed by the appropriate Alexa Fluor-conjugated secondary antibodies (1:1000, Invitrogen) for 1 h at room temperature. Images were captured using a Leica SP8 confocal microscope. Immunolabeling for cAMP was conducted using cAMP antibodies (1:200; catalog #07-1497, Millipore) in combination with the DAB procedure (Havekes et al., 2007). Optical density measurements in the corpus callosum were used to correct for background labeling. DAB images were captured using a Fisher Scientific light microscope, and optical density measurements were conducted using ImageJ.

Behavioral assays. The object–place recognition task, fear-conditioning task, open field task, and zero maze task were conducted as described previously (Trettter et al., 2009; Oliveira et al., 2010; Havekes et al., 2012b, 2014). Training and testing was conducted between ZT0 and ZT4.

Cell culture studies. Neurons (100,000/ml of C57BL/6J mouse hippocampus) were plated in a 24-well dish with coated coverslips. A week later, we transduced the neurons with AAV vectors expressing VSVG-tagged PDE4A5 (PDE4A5-VSVG) and HA-tagged PDE4A5 N-terminal truncated mutant (PDE4A5delta4-HA). At 7 days post-transduction, the neuronal cells were fixed with 4% paraformaldehyde in PBS and incubated with one of the following antibodies: GAPDH (1:1000; K1511, Santa Cruz Biotechnology); HA tag (1:1000; catalog #1867423, Roche); and VSV tag (1:2000; catalog #1874, Abcam). Immunohistochemistry was performed using the ICUE3 biosensor, as described previously (Vecsey et al., 2009). Optical imaging chamber maintained at 32°C and continually perfused with 1 l/min HEPES buffer (135.4 mM NaCl, 4 mM KCl, 25 mM HEPES, and 1 mM MgCl₂) to saturate the perfusion energy transfer (FRET) channels with the following settings: for Cerulean: excitation (ex), LED 455 nm; emission (em), 475/40 nm; for FRET: ex, LED 455 nm; em, 535/25 nm. The time course of the experiment contained the following three phases: 5–7 min baseline; 25 min of 30 μM Forskolin (FK; Tocris Bioscience); followed by 10 min of 100 μM 3-isobutyl-1-methylxanthine (IBMX; Tocris Bioscience) to saturate the cAMP response. Images were converted into grayscale values, and the dendritic fluorescent intensities were measured with ImageJ after background correction. The ratio of Cerulean and FRET was calculated for each time point.

Statistical analyses. Data analysis was performed using SPSS version 20 (SPSS). Data were analyzed using one-way or two-way ANOVAs (in some cases with repeated measures as the within-subject variable), independent-sample t tests, paired t tests, or one-way ANOVAs combined with Tukey post hoc tests. Differences were considered statistically significant at p < 0.05. All data are plotted as the mean ± SEM.

Results

Overexpression of PDE4A5 in hippocampal excitatory neurons increases PDE4 activity and reduces cAMP levels

Virtually induced PDE4A5 expression was observed in excitatory neurons throughout the hippocampus (Fig. 1A–E). Double-labeling studies using GFAP as a marker for astrocytes suggested that expression was restricted to neurons (Fig. 1F–H). Biochemical analyses confirmed the virally induced increase in PDE4A5 protein levels in hippocampal lysates (eGFP, n = 4; PDE4A5, n = 4; t(7) = −6.84; p = 0.001; Fig. 1J) and elevated PDE4 activity (eGFP, n = 10; PDE4A5, n = 9; t(17) = 13.67; p = 0.0001; Fig. 1J), with a lack of a change in non-PDE4 CAMP hydrolyzing activity (t(17) = −0.77; p = 0.453; Fig. 1J). Increased hippocampal PDE4 activity caused reduced cAMP levels in the hippocampus (eGFP, n = 5; PDE4A5, n = 5; t(7) = 3.94; p = 0.0056; Fig. 2A), but not in either the prefrontal cortex or cerebellum (t(10) = 0.35, p = 0.732, and t(8) = −1.16, p = 0.279, respectively; Fig. 2A). A reduction in CAMP immunoreactivity was evident in all three major hippocampal regions (eGFP, n = 8; PDE4A5, n = 8; CA1, t(14) = 2.10, p = 0.029; CA3, t(14) = 2.50, p = 0.026; DG, t(14) = 2.51, p = 0.025; Fig. 2B,C), but not in the amygdala (AMY; t(14) = −0.33; p = 0.372; Fig. 2B,C). Together, these data indicate that the overexpression of PDE4A5 in hippocampal excitatory neurons increases PDE4 activity and reduces CAMP levels in the hippocampus without affecting CAMP content in other brain regions.

Elevated hippocampal PDE4A5 levels attenuate CAMP-dependent synaptic plasticity

Initial electrophysiological characterization of synaptic transmission in the Schaffer collateral–CA1 pathway involved measuring basal synaptic transmission and paired-pulse facilitation (PPF), an index of short-term plasticity. Increased PDE4A5 protein levels did not alter basal synaptic transmission (eGFP, n = 8; PDE4A5, n = 8; t(14) = 1.37; p = 0.192; Fig. 3A) or PPF (eGFP, n = 9; PDE4A5, n = 9; ANOVA, effect of virus, F(1,16) = 0.024, p = 0.879; Fig. 3B). Maximum fEPSP slopes were not significantly different between groups (eGFP, n = 9, −10.56 ± 1.12 mV/ms; PDE4A5, n = 9, −10.45 ± 1.55 mV/ms; t(12) = 0.06; p = 0.949). Bath application of FK activates adenylyl cyclases, leading to increased intracellular CAMP levels and synaptic potentiation (Vecsey et al., 2009; Havekes et al., 2012b; Park et al., 2014). PDE4A5 overexpression reduces the synaptic potentiation following application of forskolin (50 μM) with a significant reduction in the mean fEPSP slope over the last 20 min of the recording (eGFP, 175.7 ± 17.7%; PDE4A5, 109.4 ± 21.0%; t(11) = 2.42; p = 0.025).
Increasing PDE4A5 in the hippocampus attenuates the formation of long-term context–shock associations.

We first assessed whether selective overexpression of PDE4A5 in hippocampal neurons increases PDE4A5 protein levels and PDE4 activity. A, Mice were bilaterally injected with AAV9-CaMKII-eGFP or AAV9-CaMKII-PDE4A5-VSV into the hippocampus. B, Viral PDE4A5 protein expression was restricted to the hippocampus. C–E, Viral expression of PDE4A5 was observed in all three major hippocampal subregions. F–H, Transgene expression was not observed in hippocampal astrocytes (PDE4A5-VSV, red; GFAP, green; bottom). I, A representative immunoblot for PDE4A5 protein levels. Viral overexpression of PDE4A5 leads to significantly higher PDE4A5 protein levels in hippocampal lysates. J, Overexpression of PDE4A5 significantly increases PDE4 activity without affecting non-PDE4 activity. All error bars denote SEM. ***p = 0.001, ****p = 0.0001.

0.035; Fig. 3C). This finding suggests that cAMP-dependent synaptic plasticity in the hippocampus is impaired by elevating PDE4A5 levels. In future studies, it will be interesting to determine whether PDE4A5 overexpression also reproduces deficits in other long-lasting forms of LTP known to be attenuated by sleep deprivation, such as LTP induced by spaced four-train or theta burst stimulation (Vecsey et al., 2009; Prince et al., 2014).

Figure 1. Overexpression of PDE4A5 in hippocampal excitatory neurons increases PDE4A5 protein levels and PDE4 activity. A, Mice were bilaterally injected with AAV9-CaMKII-eGFP or AAV9-CaMKII-PDE4A5-VSV into the hippocampus. B, Viral PDE4A5 protein expression was restricted to the hippocampus. C–E, Viral expression of PDE4A5 was observed in all three major hippocampal subregions. F–H, Transgene expression was not observed in hippocampal astrocytes (PDE4A5-VSV, red; GFAP, green; bottom). I, A representative immunoblot for PDE4A5 protein levels. Viral overexpression of PDE4A5 leads to significantly higher PDE4A5 protein levels in hippocampal lysates. J, Overexpression of PDE4A5 significantly increases PDE4 activity without affecting non-PDE4 activity. All error bars denote SEM. ***p = 0.001, ****p = 0.0001.

postshock, t(26) = −0.20, p > 0.84; Fig. 4A) but resulted in reduced freezing levels during re-exposure to the training context 24 h after conditioning (eGFP, 41.9 ± 2.7%; PDE4A5, 29.3 ± 3.0%; t(26) = 3.06, p = 0.005; Fig. 4A). Because short-term contextual fear memories do not rely on cAMP signaling (Bourtchouladze et al., 1998), we hypothesized that PDE4A5 overexpression would not affect short-term memory formation for context–shock associations. Consistent with this, increasing PDE4A5 protein levels did not alter freezing levels during training (eGFP, n = 9; PDE4A5, n = 9; preshock, t(16) = −0.18, p = 0.85; postshock, t(16) = 0.87, p = 0.39; Fig. 4B), or the findings of a retention test 1 h after training (t(16) = 0.48, p > 0.85, p = 0.64; Fig. 4B). Thus, increasing PDE4A5 protein levels specifically affects the consolidation of long-term contextual fear memories.

Tone-cued fear conditioning is a task in which rodents associate a tone [conditioned stimulus (CS)] with a mild electrical shock (unconditioned stimulus), a process that requires the amygdala rather than the hippocampus (LeDoux, 2000). Mice (eGFP, n = 12; PDE4A5, n = 13) overexpressing PDE4A5 expressed similar freezing levels during the conditioning (preshock, t(23) = 0.80, p = 0.43; CS; t(23) = 1.06, p = 0.30; postshock, t(23) = 0.54, p = 0.60; Fig. 4C). Twenty-four hours after training, mice were exposed to a novel context and re-exposed to the CS. Both groups showed similar freezing levels during exposure to the novel context (t(23) = −0.66, p = 0.51; Fig. 4C), and exposure to the CS (t(23) = 0.26, p = 0.80; Fig. 4C). Thus, tone-cued fear conditioning is not affected by the overexpression of PDE4A5 in hippocampal neurons.

PDE4A5 differs from other isoforms by virtue of a 102 aa unique N-terminal targeting domain (Beard et al., 2002; Bolger et al., 2003). To determine whether PDE4A5 requires this domain to target signaling complexes critical for the formation of context–shock associations, we engineered a truncated version of PDE4A544 that lacks the first 303 bp encoding the PDE4A544 (Bolger et al., 2003) and virally expressed this N-terminally truncated species in hippocampal neurons. In contrast to full-length PDE4A5, this truncated version failed to impair long-term memory for context–shock associations (t(15) = −1.10, p > 0.28; Fig. 4D). To further assess the specificity of the PDE4A5-mediated long-term memory deficit, we replicated the experiment, but now increased the levels of the PDE4A1 isoform. This short PDE4A isoform is exclusively membrane associated, with a major fraction of PDE4A1 found compartmentalized to the Golgi (Shakur et al., 1995; Pooley et al., 1997). In contrast to the increased expression of PDE4A5, elevated protein levels of PDE4A1 in hippocampal neurons did not...
Overexpression of PDE4A5 in hippocampal excitatory neurons attenuates the consolidation of long-term object–place memories

To examine the impact of PDE4A5 overexpression on a nonaversive hippocampus-dependent task, we turned to the object–location memory paradigm in which mice have to learn and remember the location of individual objects (Oliveira et al., 2010; Havekes et al., 2014). Mice expressing eGFP (n = 14) or PDE4A5 (n = 15) gradually reduced object exploration levels across the training sessions, indicating that animals acquired the locations of the individual objects (eGFP: session 1, 18.9 ± 1.2 s; session 2, 13.0 ± 1.2 s; session 3, 13.2 ± 2.0 s; PDE4A5: session 1, 24.1 ± 2.2 s; session 2, 18.4 ± 1.8 s; session 3, 13.7 ± 1.7 s; ANOVA effect of session, F(2,54) = 34.9, p = 0.0001). Overall, PDE4A5 mice showed slightly elevated exploration levels (ANOVA, effect of virus, F(1,27) = 4.756, p = 0.038). During the test session 24 h after training, eGFP mice preferentially explored the displaced object, indicating that they successfully remembered the previous location of the individual objects. In contrast, mice overexpressing PDE4A5 explored all objects to a similar extent, which is indicative of a poor memory for the original object locations (eGFP, 49.8 ± 5.2%; PDE4A5, 31.3 ± 3.1%; t(27) = 3.11; p = 0.004; Fig. 4E).

The novel object recognition task is based on the natural tendency of rodents to explore novel objects (Ennaceur and Delacour, 1988; Oliveira et al., 2010). Because the training conditions we use do not require an intact hippocampus (Oliveira et al., 2010), we anticipated that object–identity memories should not be affected by the overexpression of PDE4A5 in hippocampal neurons. During training, eGFP (n = 8) and PDE4A5 (n = 10) mice showed no preference for either object (Fig. 4F), although the total object exploration levels were elevated in the mice overexpressing PDE4A5 (eGFP, 20.9 ± 1.1%; PDE4A5, 31.3 ± 3.1%; t(16) = -3.923; p < 0.005). During the test session 24 h after training, both groups preferentially explored the novel object, indicating that they successfully discriminated the novel object from the familiar object (ANOVA, effect of object preference: F(1,16) = 18.623, p = 0.001; ANOVA, effect of virus: F(1,16) = 0.274, p = 0.608; interaction effect, F(1,16) = 0.013, p = 0.912; Fig. 4F).

To determine whether N-terminal-mediated targeting of PDE4A5 was essential for the ability of PDE4A5 to regulate the formation of object–place memories, we again expressed the N-terminal truncated form of PDE4A5, referred to as PDE4A5Δ4, in hippocampal neurons and trained mice in the object–location memory task. During the retention test and then some 24 h after training, both groups preferentially explored the displaced object (eGFP, n = 8; PDE4A5Δ4, n = 9; ANOVA, effect of object: F(1,15) = 25.217, p = 0.0001; ANOVA, effect of virus: F(1,15) = 0.36, p = 0.852; Fig. 4G). Next, we assessed whether elevated expression of the short PDE4A isoform PDE4A1, which targets the Golgi (Shakur et al., 1995; Pooley et al., 1997), would similarly attenuate the formation of object–location memories. In line with our fear-conditioning results, increased expression of
PDE4A5, we measured cAMP responses using the ICUE3 biosensor in hippocampal neurons expressing a control vector, full-length PDE4A5, or the N-terminal domain lacking PDE4A5. Baseline FRET responses were not affected by the overexpression of either construct (ANOVA, effect of construct: $F_{(2,44)} = 1.984, p = 0.198$; Fig. 5A, B). The expression of PDE4A5, but not PDE4A5, attenuated the forskolin-mediated FRET response (ANOVA, effect of construct: $F_{(2,44)} = 11.991, p < 0.001$; PDE4A5 vs control, Tukey test, $p < 0.01$; PDE4A5 vs PDE4A5, Tukey test, $p = 0.001$; Fig. 5A, B). Consecutive bath application with the PDE inhibitor IBMX normalized the FRET responses (ANOVA, effect of construct, $F_{(2,44)} = 0.295, p = 0.746$; Fig. 5A, B), indicating that the decrease in FRET response due to the overexpression of PDE4A5 was not a result of nonspecific alterations in PDE/cAMP signaling. Together, these data indicate that the N-terminal domain of PDE4A5 plays a critical role in the localization of PDE4A5 to specific intracellular domains, where it hampers local cAMP-dependent processes critical for synaptic plasticity and memory.

**The N-terminal domain of PDE4A5 plays an essential role in the compartmentalization of PDE isoforms**

Our behavioral data suggest that the N-terminal domain of PDE4A5 plays an essential role in the compartmentalization of the PDE4A5 isoform to cAMP-containing complexes that are critical for learning and memory. Therefore, we virally expressed full-length and truncated N-terminal-lacking PDE4A5 in cultured hippocampal neurons to compare the intracellular distribution of these isoforms. We found that the focus of full-length PDE4A5 immunofluorescence in the cultured neurons is in both a discrete perinuclear area and in dendritic compartments (Fig. 6, left). In contrast, truncated PDE4A5 lacking the N-terminal domain unique for this isoform was located predominantly in the perinuclear region (Fig. 6, middle). These findings confirm previous work (Houslay et al., 1998; Huston et al., 2000) highlighting the importance of isoform unique N-terminal domains in determining the intracellular distribution of PDE4A enzymes.

**Discussion**

Phosphodiesterases play an essential role in orchestrating the compartmentalized degradation of cAMP, leading to local changes in cAMP signaling in specific subcellular domains in the cell (Houslay, 2010). This is in part achieved by isoform-specific N-terminal domains that bind to specific localized protein complexes, which enable individual PDE isoforms to target local cAMP signaling and thereby to regulate a unique set of molecular processes (Houslay, 2010). The PDE4A5 isoform has a unique 102 aa N-terminal region involved in its intracellular targeting (Beard et al., 2002; Bolger et al., 2003). Using a viral approach, we...
show that increased selective expression of PDE4A5 in hippocampal excitatory neurons attenuates a cAMP-dependent form of synaptic plasticity in hippocampal area CA1, reduces forskolin-mediated increases in cAMP content in cultured hippocampal neurons, and impairs long-term memory formation specifically in learning tasks that require the hippocampus. Furthermore, to assess the role of the N-terminal domain of PDE4A5 in compartmentalizing and targeting cAMP-dependent signaling complexes that are critical for memory storage, we replicated the biochemical and behavioral studies using an N-terminal-lacking truncated version of the same protein. In contrast to the observations with full-length PDE4A5, the expression of the N-terminal truncated PDE4A5 construct does not attenuate forskolin-mediated alterations in cAMP responses in cultured neurons and does not affect hippocampus-dependent forms of memory, but does alter the intracellular distribution of this isoform.

Our overexpression studies with full-length PDE4A5 and PDE4A1 as well as truncated PDE4A5 emphasize that increases in the protein levels of specific PDE4 isoforms initiates the decrease in cAMP levels in specific neuronal compartments rather than causing a global nonspecific decrease in cAMP throughout the cell. Our overexpression studies suggest that the common domains shared by the different PDE4A isoforms, including the catalytic domain and the conserved regulatory regions 1 and 2 (UCR1 and UCR2), do not likely contribute to the hippocampus-dependent cognitive deficits associated with PDE4A5 overexpression. The lack of an impact of the N-terminal-lacking PDE4A5 isoform at the behavioral
level is not likely to be explained by a reduction in the efficacy of the truncated isoform to degrade cAMP, as we previously shown that the loss of the isoform-specific N-terminal domain leads to an increase rather than a decrease in catalytic activity (Beard et al., 2002).

Our findings also reveal the importance of the isoform-specific N-terminal domain for targeting individual PDE4 isoforms to cAMP signaling that is critical for cognitive processes, and confirms and expands on previous in vitro work showing that truncation of the N-terminal region of PDE4A5 alters its membrane association and localization at the cell margin (Huston et al., 2000; Beard et al., 2002; Bolger et al., 2003; Houslay, 2010). At the membrane, PDE4 isoforms can interact with molecular elements that are critical for learning and memory, such as β arrestins (Li et al., 2009). The unique N-terminal domain of PDE4A5 also allows for association with certain SH3 domain-containing proteins, such as certain members of the src tyrosyl kinase family, including Src, Fyn, and Lyn (Beard et al., 1999, 2002), and recent work indicates that Fyn inhibition reverses memory deficits in mouse models for Alzheimer’s disease (Kaufman et al., 2015). PDE4A5 also interacts with Disrupted-in-Schizophrenia 1 (DISC1; Murdoch et al., 2007), a major risk factor for schizophrenia.

**Figure 5.** Full-length but not truncated PDE4A5 attenuates FK-mediated cAMP responses assessed by a FRET indicator. A, FRET cAMP responses were measured in cultured hippocampal neurons expressing a control construct, PDE4A5, or truncated N-terminal domain-lacking PDE4A5Δ4 after consecutive bath application with the adenylate cyclase activator FK and phosphodiesterase inhibitor IBMX. Forskolin treatment significantly elevated cAMP levels in control neurons and neurons expressing PDE4A5Δ4, whereas the cAMP response was attenuated in neurons overexpressing full-length PDE4A5. B, Average FRET sensor responses for the different treatment conditions. Baseline FRET responses were not affected by the overexpression of either construct. The expression of PDE4A5, but not PDE4A5Δ4, attenuated the forskolin-mediated FRET response. Consecutive bath applications with the PDE inhibitor IBMX normalized the FRET responses. CT = 20 cells from three preparations; PDE4A5Δ4 = 11 cells from three preparations; PDE4A5Δ4 = 14 cells from three preparations. All error bars denote SEM. ***p = 0.001.

**Figure 6.** Loss of the isoform-unique N-terminal domain alters the compartmentalization of PDE4A5 in hippocampal neurons. Full-length PDE4A5 is compartmentalized to both a discrete perinuclear area and dendritic compartments (left panels). In contrast, truncated PDE4A5 lacking the N-terminal domain that is unique for the isoform was located predominantly in the perinuclear region (middle panels). PDE4A5 expression is absent from the nucleus (right panels).
nia and other psychiatric diseases, such as bipolar disorder and depression (Porteous and Millar, 2006). Therefore, the misregulation of DISC1-related signaling mechanisms may contribute to the endophenotypes associated with the overexpression of PDE4A5. The N-terminal domain of PDE4A5 also binds the immunophilin XAP2 (also called AIP and ARA9; Bolger et al., 2003), although, to our knowledge, no studies have examined the role of XAP2 in learning and memory. Deletion of the unique part of the N-terminal domain also disrupts the focus of PDE4A5 localization within ruffles at the cell margin (Beard et al., 2002). Because membrane ruffles play an essential role in cell motility and spine dynamics and through the remodeling of the actin cytoskeleton (Chhabra and Higgs, 2007; Honkura et al., 2008), one additional mechanism through which PDE4A5 could affect memory formation is by negatively impacting cAMP-dependent signaling mechanisms that modulate actin dynamics. Future studies including coimmunoprecipitation and colocalization experiments with the N-terminal domain-binding proteins will have to define whether these candidate mechanisms indeed contribute to the plasticity deficits and memory impairments associated with elevated expression of this isoform.

Sleep deprivation negatively impacts cognitive processes, particularly those that require the hippocampus (Havekes et al., 2012a; Abel et al., 2013; Kreutzmann et al., 2015). We previously found that a single brief period of sleep deprivation elevated PDE4 activity and reduced cAMP levels in the hippocampus. These changes were accompanied by a specific increase in PDE4A5 protein expression without affecting the protein levels of other PDE4 isoforms, such as PDE4B, PDE4D3, and PDE4D5 (Vecsey et al., 2009). The memory deficits associated with a single 5 h period of sleep deprivation could be prevented by pharmacological inhibition of the PDE4 family (Vecsey et al., 2009) and by transiently increasing cAMP levels selectively in hippocampal neurons (Havekes et al., 2014). Despite these observations, it remains to be defined whether the increase in PDE4A5 function in the hippocampus was causally related to the memory and plasticity deficits and memory impairments associated with sleep loss. In our current study, we observed that increasing hippocampal PDE4A5 levels impairs long-term memory formation in contextual fear conditioning and object–place recognition tasks (Fig. 4). In both learning paradigms, the formation of long-term memories critically depends on proper hippocampal function (LeDoux, 2000; Oliveira et al., 2010), and the observed impairments in both tasks mimic those observed with sleep deprivation (Graves et al., 2003; Vecsey et al., 2009; Hagewoud et al., 2010; Florian et al., 2011; Havekes et al., 2012a, 2014; Abel et al., 2013). Using electrophysiological recordings, we show that increasing PDE4A5 protein levels impairs forskolin-induced synaptic plasticity (Fig. 3), a deficit that also occurs after 5 h of sleep deprivation (Vecsey et al., 2009). In summary, this work reveals that the elevated expression of the PDE4A5 isoform in hippocampal neurons is sufficient to mimic electrophysiological and cognitive phenotypes associated with sleep loss.

To our knowledge, this work is the first to define the function of the PDE4A5 isoform and protein domains in hippocampal function. From a broader perspective, our work will help to define the contribution of individual PDE isoforms to the endophenotypes of neurocognitive and neuropsychiatric disorders that are accompanied by altered PDE signaling and facilitate the development of novel therapeutic strategies based on the targeting of specific domains of individual PDE isoforms. Related to this notion, there is now a wealth of evidence consistent with the idea that the evolutionary conserved diversity of N-terminal regions that define specific PDE4 isoforms is related to their recruitment to specific signaling complexes (Houslay, 2010). We, and others, have demonstrated that such interactions can be disrupted using cell-permeable peptides and also that such species can phenocopy dominant-negative approaches (Smith et al., 2007; Serrels et al., 2010; Martin et al., 2014). Indeed, an engineered peptide disrupting PDE4D–HSP20 interactions shows in vivo efficacy in a mouse model of pressure overload-mediated hypertrophy (Martin et al., 2014). The ability to refine such disruptor peptides for in vivo use could be facilitated through the use of nuclear magnetic resonance to uncover their structure (Smith et al., 2007), together with the incorporation of non-native amino acids and the addition of lipid species to facilitate cell entry together with truncation and modification to generate peptidomimetic species. Identification of the functional anchor species for PDE4A5 in this scenario would then take developments to a level where high-throughput screening for small-molecule, drug-like disruptor species of PDE4A5 and its functional anchor becomes a realistic approach. Additionally, high content screens for compounds that dislocate PDE4A5 from its relevant compartment in cells would provide another means of such compounds. The aim would be to uncover small peptides and peptidomimetics of small molecules that enter the brain and dislocate PDE4A5 from the functionally relevant anchor protein/signaling complex to recapitulate the phenotype we describe in these studies.

References


